database / metabolic
Cagrilintide
Skeletal structure drawn from the computed atomic coordinates in PubChem CID 171397054. Carbons are implicit vertices; hydrogens on carbon are suppressed, as in any structural formula. Nothing here is estimated — every atom sits where PubChem placed it.
Research reference only. The observations below are recorded in the cited literature. Nothing here is advice or a recommendation, and no dosing information is published on this site.
Sequence
Primary structure not characterised in the public records this index draws on. Nothing is shown rather than something invented.
A long-acting amylin analogue with a fatty-acid conjugate; the full structure is not transcribed here rather than risked.
Molecular data
| molecular formula | C194H312N54O59S2 |
|---|---|
| molecular weight | 4409 Da (PubChem) |
| computed backbone mass | not characterised |
| length | not characterised |
| net charge (pH 7.4) | not characterised |
| mean hydropathy | not characterised |
| half-life | not characterised |
| delivery route | subcutaneous |
| PubChem CID | 171397054 |
| PDB | not characterised |
| UniProt parent | not characterised |
Mechanism
Amylin receptor agonist, studied in combination with GLP-1 agonists.
Reported targets: AMY receptors
Experimental structure
No experimental structure of this peptide is deposited in the PDB. Nothing is rendered here — a predicted fold would not be a structure, and this site does not draw one.
Reported effects
Each row is an outcome described in the literature indexed for this peptide. Reported in the cited work — not a claim, not a recommendation.
| reported outcome | where it appears |
|---|---|
| weight loss | Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in a… The lancet. Diabetes & endocrinology 2026 |
| appetite suppression | Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in p… The lancet. Diabetes & endocrinology 2026 |
Registered trials
| NCT | title | status | phase |
|---|---|---|---|
| NCT07564414 | A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide | RECRUITING | PHASE3 |
| NCT07527195 | Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role | RECRUITING | PHASE1 |
| NCT06207877 | A Research Study to Look at How CagriSema Influences Food Intake, Appetite and Emptying of t | COMPLETED | PHASE1 |
| NCT06323161 | A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Pl | COMPLETED | PHASE3 |
| NCT07357766 | A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People | WITHDRAWN | PHASE3 |
Literature (8)
Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study — The lancet. Diabetes & endocrinology 2026
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · PMID 42251860 · DOI 10.1016/s2213-8587(26)00126-9
Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study — The lancet. Diabetes & endocrinology 2026
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · PMID 42251859 · DOI 10.1016/s2213-8587(26)00125-7
A cross-species atlas of the dorsal vagal complex reveals neural mediators of the effects of cagrilintide on energy balance — Nature metabolism 2026
Amylin receptor agonists such as cagrilintide represent emerging obesity therapies. To understand mediators of cagrilintide action, we generated a transcriptomics atlas of over 530,000 cells comprising 80 neuronal cell populations across rat, mouse and macaque caudal brainstem, with spatial profiling to map distribution in the rat dorsal vagal complex (DVC). Here we show that cagrilintide regulates two conserved Calcr-expressing DVC neuronal populations. While acute cagrilintide treatment alters gene expression in area postrema Calcr/Ramp3 neurons, chemogenetic activation in rats fails to affect long-term food intake and body weight. In contrast, long-term cagrilintide treatment in rats upregulates prolactin-releasing hormone (Prlh) expression in nucleus of the solitary tract Calcr/Prlh cells that are conserved across rodents, macaques and humans. Knocking down DVC Prlh abrogates the eff…
open access ↗ · PMID 42260119 · DOI 10.1038/s42255-026-01539-3
Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study — Lancet (London, England) 2026
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · PMID 42251856 · DOI 10.1016/s0140-6736(26)01022-6
Maximizing weight loss with cagrisema: a systematic review and GRADE-assessed meta-analysis of randomized controlled trials — Naunyn-Schmiedeberg's archives of pharmacology 2026
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · PMID 42608559 · DOI 10.1007/s00210-026-05809-5
Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo — Annals of medicine and surgery (2012) 2026
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · PMID 42583410 · DOI 10.1097/ms9.0000000000005353
Cagrilintide and CagriSema for weight reduction and metabolic risk modification in overweight or obesity: a systematic review and meta-analysis — Journal of diabetes and metabolic disorders 2026
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · PMID 42180166 · DOI 10.1007/s40200-026-01942-3
Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide — Clinical pharmacokinetics 2026
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · PMID 42228334 · DOI 10.1007/s40262-026-01654-0
Related
Teduglutide
metabolic · 8 citations
Pramlintide
metabolic · 8 citations
Leptin fragment (116-130)
metabolic · 6 citations
AOD-9604
metabolic · 8 citations
HGH Fragment 176-191
metabolic · 2 citations
Linaclotide
metabolic · 8 citations